

## Macro Roundup Article

**Headline:** [Today's Most Important Technology](#)

**Article Link:** <https://www.exponentialview.co/p/todays-most-important-technology>

Author(s)	Azeem Azhar and Nathan Warren
Publication	Exponential View
Publication Date	August 21, 2024

**Tweet:** [@ExponentialView](#) argues that GLP-1 agonists like Ozempic and Mounjaro “will be the most impactful technology in the US over the next two years,” countering the \$2T global economic costs of overweight and obesity, projected to double by 2035.

**Summary:** While GLP-1s were initially focused on patients with type 2 diabetes, their effectiveness for weight management has seen demand grow outside of their initial treatment purpose. In 2019, fewer than 10% of patients on semaglutide were taking it for weight control. By the middle of last year, that proportion surged to 41.7%. Besides bolstering the pockets of big pharma, the economic potential of GLP-1s comes in its second and third-order impacts. 1 in 8 people worldwide are living with obesity. Alongside those who are overweight, they cost the global economy \$2 trillion. Nearly 70 cents in the dollar is due to indirect costs – premature mortality and productivity losses associated with ill health. Without intervention, this impact is expected to double by 2035.

**Related Articles:** The Year of Ozempic and How Weight Loss Drugs Stopped a Danish Recession

**Primary Topic:** Innovation/Research

**Topics:** GDP, Growth, Innovation/Research, Op-Ed/Blog Post, Productivity

**Permalink:** <https://www.edwardconard.com/macro-roundup/exponentialview-argues-that-glp-1-agonists-like-ozempic-and-mounjaro-will-be-the-most-impactful-technology-in-the-us-over-the-next-two-years-countering-the-2t-global-economic-costs?view=detail>

**Featured Image Link:** <https://www.edwardconard.com/wp-content/uploads/2024/08/22808-todays-most-important-technology-featured-thumbnail-image.png>